Published in
Springer, PharmacoEconomics, 9(40), p. 917-928, 2022
DOI: 10.1007/s40273-022-01169-z
Links
Tools
The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 